Welcome to our dedicated page for GE HealthCare Technologies news (Ticker: GEHC), a resource for investors and traders seeking the latest updates and insights on GE HealthCare Technologies stock.
GE HealthCare Technologies Inc. (NYSE: GEHC) is a leading global innovator in medical technology, pharmaceutical diagnostics, and digital solutions. The company operates through four main segments: Imaging, Ultrasound, Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Of these, the Imaging segment generates the majority of the company’s revenue.
GE HealthCare is dedicated to providing transformational medical technologies and services that enhance access to quality, affordable healthcare worldwide. Through its cutting-edge products and comprehensive solutions, the company aims to improve patient outcomes and streamline healthcare delivery.
Recent achievements include advancements in artificial intelligence (AI) integration within medical imaging, which supports more accurate and efficient diagnostics. The company is also involved in numerous partnerships with healthcare providers and research institutions to drive innovation and improve global healthcare standards.
Financially, GE HealthCare has showcased robust performance, with steady revenue growth and strong market presence. The company continuously invests in R&D to maintain its edge in the competitive healthcare industry. Their suite of products includes advanced imaging machines, ultrasound devices, patient monitoring systems, and contrast media for diagnostic imaging.
As part of a highly regulated industry, GE HealthCare adheres to strict compliance standards and maintains rigorous quality controls across its operations. The company actively engages with its community, although it reserves the right to monitor and manage public interactions to uphold professional and constructive discourse.
Rhea-AI Summary
GE HealthCare has received FDA clearance for an expanded indication for Novii+ maternal and fetal monitoring solution for pregnant patients ≥34 weeks. The Novii+ noninvasively measures and displays fetal heart rate, maternal heart rate, and uterine activity, providing patient comfort and mobility in the hospital. The wireless design enables mobility and freedom for mothers, and studies have shown that it may help decrease the length of labor. Novii+ is an expanded indication from the Novii Maternal and Fetal Monitoring Solution that utilizes an updated algorithm to improve reliability and accuracy. It can be used for both antepartum and intrapartum pregnant patients 34 weeks and greater, which extends usage before the previously defined use of 37 weeks and greater of pregnancy. The expanded indication is based on data submitted to the FDA to determine Novii+ Wireless Patch Solution’s equivalence to doppler fetal heart rate, tocodynamometer uterine activity, and pulse oximetry maternal heart rate devices for preterm patients (≥34 weeks) in terms of accuracy and reliability. It is a first-of-its-kind patch-based antepartum and intrapartum monitoring solution for preterm patients (≥34 weeks). The Novii+ Wireless Patch Solution will be available to customers in the United States later this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.35%
Tags
-
Rhea-AI Summary
GE HealthCare (Nasdaq: GEHC) announces the latest innovation in electrophysiology (EP), the Prucka 3 with CardioLab EP Recording system, to help clinicians in the diagnosis and treatment of cardiac arrhythmias. The new platform maintains high signal fidelity, reduces environmental noise, and offers advanced analytics for the diagnosis and treatment of cardiac arrhythmias. The prevalence of AFib is projected to affect millions globally, making the need for accurate and efficient recording systems crucial. The new Prucka 3 system is designed to address these needs and enable path to new technologies in the EP lab.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
-
Rhea-AI Summary
GE HealthCare (Nasdaq: GEHC) will announce its Q4 and full year 2023 financial results on February 6, 2024. A live webcast and conference call will be hosted by the management team at 8:30 a.m. Eastern Time. The webcast replay and financial information will be available on the GE HealthCare Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
Rhea-AI Summary
GE HealthCare (GEHC) announced the acquisition of MIM Software, a global provider of medical imaging analysis and artificial intelligence (AI) solutions for the practice of radiation oncology, molecular radiotherapy, diagnostic imaging, and urology. The acquisition aims to strengthen GE HealthCare's digital solutions across care pathways, reinforcing its commitment to integrating medical imaging products for more precise, connected, and efficient care across disease states.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
-
Rhea-AI Summary
GE HealthCare (GEHC) executives to attend 42nd Annual J.P. Morgan Healthcare Conference. President and CEO, Peter Arduini, and CFO, Jay Saccaro, will participate in a Q&A session on January 9th. The live webcast can be accessed on GE HealthCare's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
-
Rhea-AI Summary
GE HealthCare Technologies Inc. (Nasdaq: GEHC) declares a cash dividend of $0.03 per share of Common Stock for the fourth quarter of 2023, payable on February 15, 2024, to all shareholders of record as of January 16, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.68%
Tags
Rhea-AI Summary
GE HealthCare (GEHC) and AirStrip announced a joint commercialization agreement, making GEHC the exclusive distributor of AirStrip Cardiology and Patient Monitoring solutions in the U.S. This collaboration provides healthcare systems with deeply integrated offerings and a comprehensive ecosystem of solutions to enhance patient care and outcomes. The partnership aims to support providers and clinical staff in enabling efficient workflow and patient monitoring in near real time across mobile devices and the web.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.06%
Tags
-
Rhea-AI Summary
GE HealthCare (NASDAQ: GEHC) introduces True Enhance DL to its Effortless Recon DL portfolio, leveraging deep learning for CT imaging. The company aims to improve image quality and clinical decision-making for neurology, oncology, and cardiology to benefit patients globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
-
Rhea-AI Summary
GE HealthCare (GEHC) announces FDA 510K clearance for Critical Care Suite 2.1 with Pneumothorax (PTX) algorithm. The on-device AI detects and localizes PTX, reducing reporting times by 57% and increasing clinician detection of small PTXs by 17.7%. The algorithm has 100% partial localization accuracy for large PTXs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.23%
Tags
Rhea-AI Summary
GE HealthCare (GEHC) introduces MyBreastAI Suite, an all-in-one AI platform for mammography, integrating three AI applications from iCAD to aid clinicians in breast cancer detection, breast density assessment, and notification. The platform aims to combat increasing challenges faced by radiologists and health systems, such as burnout, workforce attrition, and patient backlogs. MyBreastAI Suite will be available in the United States and will be distributed, installed, and supported by GE HealthCare as part of the company’s Senographe Pristina mammography portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.49%
Tags
FAQ
What is the current stock price of GE HealthCare Technologies (GEHC)?
The current stock price of GE HealthCare Technologies (GEHC) is $86.93 as of February 4, 2025.
What is the market cap of GE HealthCare Technologies (GEHC)?
The market cap of GE HealthCare Technologies (GEHC) is approximately 40.1B.
What does GE HealthCare Technologies Inc. do?
GE HealthCare Technologies Inc. provides transformative medical technologies, pharmaceutical diagnostics, and digital solutions to improve healthcare access and quality globally.
What are the main business segments of GE HealthCare?
The main business segments are Imaging, Ultrasound, Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx).
How does GE HealthCare generate most of its revenue?
The company generates the majority of its revenue from the Imaging segment.
What recent advancements has GE HealthCare made?
GE HealthCare has made significant advancements in AI integration within medical imaging, improving diagnostic accuracy and efficiency.
Who are GE HealthCare's partners?
The company collaborates with healthcare providers and research institutions to drive innovation and improve healthcare standards.
How does GE HealthCare ensure compliance?
GE HealthCare adheres to strict regulatory compliance standards and maintains rigorous quality controls across its operations.
What products does GE HealthCare offer?
GE HealthCare offers a range of products, including imaging machines, ultrasound devices, patient monitoring systems, and diagnostic contrast media.
What is GE HealthCare's commitment to the community?
The company engages actively with its community and strives to maintain professional and positive interactions while monitoring public posts and conversations.
How has GE HealthCare performed financially?
GE HealthCare has shown robust financial performance with steady revenue growth, supported by continuous investment in research and development.
What is GE HealthCare's mission?
GE HealthCare is committed to improving patient outcomes and making quality healthcare more accessible and affordable worldwide.
GE HealthCare Technologies Inc.
Nasdaq:GEHC
GEHC Rankings
GEHC Stock Data
40.07B
442.77M
3.09%
84.02%
2.79%
Health Information Services
X-ray Apparatus & Tubes & Related Irradiation Apparatus
United States of America
CHICAGO